Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase EARLY_PHASE1 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 2 Esophageal Neoplasms 2 Uterine Cervical Neoplasms 1 Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1 Resectable Non-small Cell Lung Cancer 1 Ovarian Neoplasms 1 Nonsquamous Non-small Cell Lung Cancer 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Esophageal Squamous Cell Carcinoma 1

Interventions

Paclitaxel 79 Carboplatin 64 Bevacizumab 33 liposomal doxorubicin 29 Topotecan 28 Gemcitabine 25 Cisplatin 19 olaparib 18 Drug Therapy 12 Doxorubicin 12 Taxes 11 niraparib 9 Docetaxel 6 CP protocol 6 Trabectedin 5 Hyperthermic Intraperitoneal Chemotherapy 5 Etoposide 5 Cyclophosphamide 5 1-dodecylpyridoxal 5 rucaparib 4 pembrolizumab 4 avelumab 4 atezolizumab 4 Immunoglobulin G 4 Ifosfamide 4 Disulfides 4 Dexamethasone 4 Chemotherapy, Adjuvant 4 trebananib 3 fluzoparib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Ovarian Neoplasms × Platinum Compounds × Clear all

NCT02891824 2025-02-11

ATALANTE

ARCAGY/ GINECO GROUP

Phase 3 Completed

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡